Sellas Life Sciences has thrown open the door to speculation, adjusting senior management contracts in a move that market watchers interpret as a prelude to a possible change of control. The biotech firm amended the agreements for CEO Angelos Stergiou, CFO John Burns, and R&D head Dragan Cicic to include hefty one-time payouts and immediate vesting of stock options in the event of an acquisition — classic “golden parachute” provisions that typically surface when a sale is being teed up.
Investors wasted no time rewarding the signal. The stock surged more than 9% on Friday to close at €10.15, just shy of its current year high. The rally caps a stunning 12-month run: the shares have roughly six-bagged from a trough of €1.22 in November 2025, reflecting a gain of over 440%. With the relative strength index hovering around 74, however, the equity is technically in overbought territory.
The management shake-up coincides with a critical inflection point in the company’s pipeline. Sellas’ lead asset, Galinpepimut-S, is being evaluated in the REGAL Phase 3 trial for leukemia. Of the 80 events required for the final analysis, 78 have already occurred, putting the data readout within weeks. The moment the last two clinical events are recorded, the company will proceed to final analysis.
Beyond REGAL, the company is advancing SLS009, a second drug candidate now in Phase 2 testing for newly diagnosed patients. Top-line results from that study are expected in the fourth quarter of 2026 — a catalyst that could reshape the company’s valuation depending on the outcome.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
Financially, Sellas is sitting on a comfortable cushion. At the end of March, it held approximately $107 million in cash. An additional $28 million flowed into the treasury in the spring from the exercise of warrants, providing a solid runway to push through both the REGAL readout and the SLS009 data. Against that, the company posted a quarterly net loss of roughly $8 million.
The stock had been trading at €9.38 before the latest leg up, meaning the Friday jump added significant ground. The combination of near-term clinical catalysts and the golden-parachute signal has created a potent mix of takeover chatter and binary event risk.
What happens next hinges on the final two REGAL events. Once they are logged, the biotech world will watch closely for the results — and for whether the management contract changes were merely prudent housekeeping or the first step toward a sale. The coming weeks will decide.
Ad
Sellas Life Sciences Stock: Buy or Sell?! New Sellas Life Sciences Analysis from June 26 delivers the answer:
The latest Sellas Life Sciences figures speak for themselves: Urgent action needed for Sellas Life Sciences investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 26.
Sellas Life Sciences: Buy or sell? Read more here...
